Satellos Bioscience Inc · TSX:MSCL
Satellos Bioscience — Investor Presentation (February 2024)
17 slides from Satellos Bioscience's investor presentation, February 2024

Slide 1: Rebuilding muscle from within
Rebuilding muscle from within

Slide 2: Legal Disclaimers
Legal Disclaimers Certain statements in this presentation are “forward-looking statements” under applicable securities laws. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions or future events or performa

Slide 3: Corporate Mission and Highlights
Corporate Mission and Highlights We challenge conventions, break scientific ground, and urgently advance drug development, because there’s no time to waste. Our mission is to develop a new class of drugs that treat degenerative muscle conditions by resetting muscle repair and regeneration, thereby r

Slide 4: Experts in muscle stem cell biology, drug development experts, and industry veterans
Experts in muscle stem cell biology, drug development experts, and industry veterans Frank Gleeson, MBA Michael Rudnicki, Philip Lambert, PhD Liz Williams, CPA, CA Michael Cross, PhD, MBA Courtney Wells Co-Founder & CEO PhD, OC,FRS, FRSC Chief Scientific Officer Chief FinancialOfficer Chief Business

Slide 5: Satellos – attractive entrance point
Representative Comparators1 Satellos – attractive Market Caps at entrance point Feb. 15, 2024 1 Clinical Stage Phase 1 Phase 2 - 200,000 200 400,000 400 600,000 600 800,000 800 1,000,000 1,000 1,200,000 1,200 1,400,000 1,400 Phase 1/2 Phase 3 Market Capitalization (USD$million) 1. Representative com

Slide 6: Duchenne muscular dystrophy: the patient journey
Duchenne muscular dystrophy: the patient journey 1:5,000 male babies born annually with Duchenne, a fatal genetic disease. Mutation(s) in the dystrophin gene leads to a loss or dysfunction of the dystrophin protein. Satellos discovery: the dystrophin protein is needed in muscle stem cells for

Slide 7: Regeneration is severely compromised in Duchenne
Regeneration is severely compromised in Duchenne: due to the absence of dystrophin in muscle stem cells Healthy muscle fibers Duchenne muscle fibers Dystrophin in muscle stem cells Without dystrophin in muscle stem enables regeneration cells, regeneration is blunted Muscle stem cell Regeneration Mus

Slide 8: The role of dystrophin in muscle stem cells can be replaced to restore muscle regeneration
The role of dystrophin in muscle stem cells can be replaced to restore muscle regeneration Dystrophin plays a signal transduction role in directing asymmetric stem cell divisions1 symmetric division asymmetric division Muscle regenerates through asymmetric divisions of dystrophin stem cells into

Slide 9: Satellos lead drug candidate increases progenitor formation and muscle strength in a mouse model of DMD
Satellos lead drug candidate increases progenitor formation and muscle strength in a mouse model of DMD Lead drug candidate: SAT-3247 In vitro MyoReGenX Study In vivo 28-day Treatment Study **** p<0.00001 mdx mice n = 10/group SAT-3247 increases progenitor cell formation SAT-3247 increases muscle fo

Slide 10: Duchenne patients walk without any muscle dystrophin
Duchenne patients walk without any muscle dystrophin The discovery that Duchenne patients were ambulatory, despite having no muscle dystrophin, provides genetic proof of concept that it is possible to have functional muscle in the absence of dystrophin. Also, this report, as well as additional repor

Slide 11: All Duchenne patients have the potential to benefit from Satellos therapeutic approach
All Duchenne patients have the potential to benefit from Satellos therapeutic approach Therapeutic approaches for Duchenne can be classified into two categories: Dystrophin Dependent Dystrophin Independent Genetic medicines to enhance dystrophin in Activation of a dystrophin-independent pathway to m

Slide 12: MyoReGenX platform powers pipeline expansion
MyoReGenX platform powers pipeline expansion Multiple muscle dystrophies Aging Muscle Injury Cachexia Sarcopenia © 2024 Satellos Biosciences 12

Slide 13: Duchenne program development plan & value catalysts
Duchenne program development plan & value catalysts Lead drug candidate: SAT-3247 IND Enabling Regulatory Regulatory Ph 1b/2a Preclinical submission submission POC Clinical Studies and to begin for POC Trial/s Toxicology Clinical Trial clinical trials Ph 1a Safety SAT-3247 and PK GMP Batch Clinical

Slide 14: Current Financials
Current Financials Background Capital Table Common Share 152.5 M Founded 2018 by repeat Warrants 12.3 M entrepreneurs, RTO on TSX.V 2021 Stock Options 13.6 M Strong 2-year cash runway Fully Diluted 178.4 M 50%+ institutional ownership Insiders: ~15% (fully diluted) Cash at 9/30/23 ~CA$44.3M Venture

Slide 15: An enormous market opportunity in which the vast majority of patients go untreated
70% of Duchenne patients remain untreated2 7,000-9,500 Duchenne patients in the US1 An enormous market opportunity in which 4 approved drugs for DMD the vast majority of patients go untreated! > $4B DMD market opportunity Multiple Indication expansion opportunities 1 Larkindale, J., Yang, W., Hogan,

Slide 16: REIMAGINE how degenerative muscle diseases are treated
REIMAGINE how degenerative muscle diseases are treated. REGENERATE with novel small molecule medicines. REALIZE the potential to improve lives.

Slide 17: Frank Gleeson, Co-Founder and CEO; Liz Williams CFO
Frank Gleeson, Co-Founder and CEO Liz Williams CFO ir@satellos.com | +1.647.660.1780 | www.satellos.com
Source: Internet Archive copy of s203.q4cdn.com
More decks from Satellos Bioscience Inc
Corporate Update (November 2026)17 slides · Nov 6, 2026
Corporate Update (July 2026)14 slides · Jul 8, 2026
2026 Bloom Burton & Co. Healthcare Investor Conference23 slides · April 2026
Technical Presentation (February 2026)52 slides · Feb 24, 2026
Investor Presentation (February 2026)21 slides · February 2026
Investor Presentation (October 2025)19 slides · October 2025